Healthcare Regulatory Affairs Outsourcing Market
Surge in R&D investment to Drive the Demand for Healthcare Regulatory Affairs Outsourcing: FMI Presents Detailed analysis in 30+ Countries
Healthcare Regulatory Affairs Outsourcing Market by Services, by End User & Region – Forecast 2023–2033
Healthcare Regulatory Affairs Outsourcing Market Outlook (2023-2033)
The healthcare regulatory affairs outsourcing market is expected to grow at a CAGR of 11.3% during the forecast period. The market is valued at US$ 2 Bn as of 2023, and by 2033, the market is expected to hit a valuation of US$ 5.8 Bn.
Some of the Factors Which are Expected to Surge the Medical Affairs Outsourcing Market Growth are:
- Increasing cases of chronic ailments
- High cost of R&D activities, which augments the volume of clinical trial applications and product registration
- Surging focus on novel drug development
Approval time of drugs and other medical equipment is a costly, time-consuming, and documentation-centric procedure, because of which the companies have to face a lot of pressure. Such situations are leading to a surging adoption of healthcare regulatory affairs outsourcing.
The functions pertaining to regulatory affairs are challenging, and a surging demand to obtain approval for the new products and maintaining the compliance is expected to surge the market share.
With increasing focus on novel drug development in the healthcare sector, various firms are partnering with outsourcing companies for faster documentation and approvals.
Apart from that, the healthcare companies which are expanding worldwide are looking for speedy approvals in local markets. This might surge the demand for healthcare regulatory affairs outsourcing during the forecast period.
Moreover, there are increasing cases of outsourcing local regulatory support in smaller and financially attractive markets while keeping activities related to high-relevance countries for the in-house management.
On the other hand, switching to CROs costs money for the organisations. The corporation may decide to adjust its outsourcing policy such that it internally sources regulatory affairs work instead, which would result in higher operational costs.
Additionally, organisations fear that outsourcing regulatory affairs work to CROs may result in the loss of important internal capabilities. Given that when outsourced regulatory knowledge is needed, the situation in a firm may be urgent, it is crucial that CROs have enough resources to acquire flexibility. These factors might induce a decline in the growth rate for the medical device affairs outsourcing market.
The Asia Pacific region is the largest market, having a share of more than 40%. The region is also expected to witness the highest CAGR during the forecast period. This can be attributed to the increasing number of companies trying to enter developing economies, such as India and China. Furthermore, the availability of a skilled workforce in the region at lower costs is also expected to drive the market growth.
|
Attributes |
Value |
|
Healthcare Regulatory Affairs Outsourcing Market Value (2022) |
US$ 1.8 Bn |
|
Healthcare Regulatory Affairs Outsourcing Market Value (2023) |
US$ 2 Bn |
|
Healthcare Regulatory Affairs Outsourcing Market Forecast Value (2033) |
US$ 5.8 Bn |
|
Healthcare Regulatory Affairs Outsourcing Market Expected CAGR (2023 to 2033) |
11.3% |
Let us know your requirement to get
100% FREE customization
Historical CAGR (2017-2022) vs Anticipated CAGR
There is hardly any difference between the historical CAGR and the anticipated CAGR. But a slight dip has been observed owing to tight regulations that were put in place during the pandemic, which presented a whole new picture of post-pandemic regulatory affairs outsourcing. While the historical CAGR was 11.8%, the anticipated CAGR is 11.3%.
Short-term growth (2023-2026): In this period, the market might witness the expansion of the healthcare sector worldwide. This would compel biotechnology and pharmaceutical companies to outsource regulatory affairs to save costs and leverage the expertise available with Contract Research Organizations (CROs). This would allow companies to save time and improve their core competencies, which is a chief driver of the market.
Medium-term growth (2026-2029): During this period, regulatory support might be available for most of the processes across clinical trials. The verticals include manufacturing and controls (CMC), medial report writing, regulatory chemistry, data management, country regulatory affairs, regulatory strategy, and labeling & liaison. This might be attributed to the fact that the market may witness growth.
Long-term growth (2029-2033): If the market continues progressing as per the analysis, the majority of the companies would outsource the non-core activities to experts. This would enable healthcare organizations to focus on their marketing and research and development activities. In the long run, companies can benefit from product approvals, optimized reimbursements, and increased productivity. Owing to these factors, the market is anticipated to witness an upward trajectory in growth over the forecast period, opines FMI.
Drivers for Healthcare Regulatory Affairs Outsourcing Market
Cost Effective Solution
The market is expected to witness an upsurge in subcontracting vital functional accomplishments, especially in field-based medical teams, medical publications and medical material. Healthcare regulatory affairs outsourcing provides an affordable and flexible solution to address challenges and demands faced by an enterprise. Moreover, the procedures associated are becoming stringent due to increased association with regulatory authorities worldwide. Apart from that, the implementation of outsourcing solutions would assist firms in reducing the number of in-house employees and prioritizing important activities. This would help the companies in optimizing the workload and centralise certain crucial functions as well, and provide efficient regulatory consulting.
Surging Investment in R&D
Increased investment in R&D has led to the development of many innovative products in the market. With stringent regulations, strategic collaborations among the clinical research firms, drug developers and CMOs might alleviate the risk. Contract Manufacturing Organisations assist the corporation to reduce risk so that companies can focus on the vital dealings. Thus, surging R&D activities coupled with patent expirations are expected to bring positiveeffects on the healthcare regulatory affairs outsourcing market key trends and opportunities.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystHow Will Optimization of Vendor Networks Impact Market?
In the last few years, the optimization of vendor networks in large pharmaceutical companies has gained traction at a significant pace. To speed up the regulatory process, companies are trying to reduce the number of vendors to ensure a consistent and higher quality service.
This also enabled companies to apply a centralized approach, reduce resources required for vendor oversight, and achieve higher effectiveness and efficiency. In addition to this, outsourcing via third-party vendors is gaining traction, which again, leads to a significant reduction in costs.
Outsourcing vendor management offers process standardization and consistency, transparency, and effective governance. This trend is more prevalent in clinical operations, however, within the last few years it has become highly sought-after in regulatory affairs and pharmacovigilance.
Further, companies are investing in innovative outsourcing services providers to ensure high-quality delivery. Large pharmaceutical companies are trying to achieve higher quality standards than the minimum target set by regulatory bodies.
By choosing innovative vendors over generic ones, companies are paying more attention to management and governance, quality and compliance, regulatory intelligence process, team experience and engagement, and the vendor's internal structure and procedures. Through this, they are attempting to speed up the clinical trials and product approval process, which is expected to boost the healthcare regulatory affairs outsourcing market in the forthcoming years.
Cost of Outsourcing to be a Major Restraint
The outsourcing cost of regulatory affairs is quite high, and the companies or organizations which opt to outsource regulatory affairs may not be in a state to conduct an in-house evaluation. Furthermore, during outsourcing, there must be risk management plan, which include considerations of cost if the outsourcing of regulatory affairs is discontinued. This as well is expected to present a dipping curve in the healthcare regulatory affairs outsourcing adoption trends.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Comparative View for Healthcare Regulatory Affairs Outsourcing Market
Healthcare Regulatory Affairs Outsourcing Market:
|
Attributes |
Healthcare Regulatory Affairs Outsourcing Market |
|
Anticipated CAGR (2023 to 2033) |
11.3% |
|
Market Value (2023) |
US$ 2 Bn |
|
Growth Factor |
Cost effective method, and rising investment in R&D |
|
Future Opportunities |
Surging focus on novel drug development |
|
Market Trends |
Optimisation of vendor networks driving the market |
Outsourced Testing Services Market:
|
Attributes |
Outsourced Testing Services Market |
|
Anticipated CAGR (2023 to 2033) |
7.7% |
|
Market Value (2023) |
US$ 39.5 Bn |
|
Growth Factor |
Prevalence of pathogenic viral disease |
|
Future Opportunities |
Increased investment in R&D by key players |
|
Market Trends |
Emerging economies are investing in this market |
Healthcare IT Outsourcing Market:
|
Attributes |
Healthcare IT Outsourcing Market |
|
Anticipated CAGR (2023 to 2033) |
7.2% |
|
Market Value (2023) |
US$ 53,500 Mn |
|
Growth Factor |
Ability to monitor health of the patient digitally |
|
Future Opportunities |
Increasing demand to curb healthcare costs |
|
Market Trends |
Market is witnessing number of cyber security threats |
Country-wise Insights
| Regions | North America |
| Countries | United States |
| CAGR (2023-2033) | 11.2% |
| Regions | Europe |
| Countries | UK |
| CAGR (2023-2033) | 12.1% |
| Regions | Asia Pacific |
| Countries | China |
| CAGR (2023-2033) | 14.1% |
| Regions | Asia Pacific |
| Countries | India |
| CAGR (2023-2033) | 17.2% |
| Regions | Asia Pacific |
| Countries | Japan |
| CAGR (2023-2033) | 12.9% |
Why is the U.S. Healthcare Regulatory Affairs Outsourcing Market Witnessing High Demand?
The U.S. is expected to emerge as a lucrative pocket owing to the presence of a robust healthcare sector and various small and large pharmaceutical and biotechnological companies. As per FMI, sales in the North American market are projected to command 30% of the total market share in 2022.
|
Attributes |
Details |
|
US Market Expected Size (2033) |
US$ 1.5 Bn |
|
US Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 978.1 Mn |
|
CAGR % 2017 to 2022 |
10.1% |
Stringent compliances issued by regulatory authorities are encouraging collaborations between drug developers and clinical research organizations (CROs) and Contract Manufacturing Organizations. (CMOs) to mitigate potential risks and speed up the approval process.
In addition to this, various generic drugs are reaching their expiration dates, which is expected to boost sales in the market. Increasing research and development for novel drugs, vaccines, and medical equipment in the U.S. will continue augmenting the growth of the market in the forthcoming years.
How will the U.K. Healthcare Regulatory Affairs Outsource Market Fare?
Demand in the Europe market is projected to account for 23% of the total market share in 2022, with the U.K. emerging as a lucrative pocket over the forecast period.
The license for marketing and authorization of new drugs in the U.K. is granted by a regulatory authority, allowing the product to be sold by a license holder in countries covered by the regulatory authority.
|
Attributes |
Details |
|
UK Market Expected Size (2033) |
US$ 245.1 Mn |
|
UK Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 167 Mn |
|
CAGR % 2017 to 2022 |
11.9% |
From January 2021, the Medicines and Healthcare Products Regulatory Agency (MHRA) carried out the licensing of new medicines in England, Scotland, and Wales. In Northern Ireland, new medicines are being licensed by the European Commission, following the recommendations from the European Medicines Agency (MEA).
Further, the National Institute for Health and Care Excellence (NICE) for England and Wales and the Scottish Medicines Consortium (SMC) for Scotland appraise certain new medicines and investigate issues such as cost-effectiveness and efficacy in new treatments.
Due to the extensive approval process, demand for outsourcing services is on the rise. This trend is expected to continue over the forecast period, thereby fueling the growth of the market.
Why is the China Healthcare Regulatory Affairs Outsourcing Market Considered Attractive?
Favorable government investments and policies in the expansion of the healthcare sector in China are expected to place it as an attractive pocket in the Asia Pacific market. Demand in the Asia Pacific market is projected to hold 27.4% of the total market share in 2022.
|
Attributes |
Details |
|
China Market Expected Size (2033) |
US$ 539 Mn |
|
China Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 394.9 Mn |
|
CAGR % 2017 to 2022 |
13.3% |
Various pharmaceutical companies are aiming to expand their presence in China, which will require them to invest in outsourcing services for documentation, clinical trial applications, product registrations, and legal representation. This is expected to continue boosting sales in the market.
Besides this, regional pharmaceutical companies are focusing on generic domestic drug pricing and reimbursement reforms, such as a government-backed centralized drug procurement policy. This ensures lower bid contracts and guaranteed sales volume of drugs.
Lower costs are encouraging generic drug industry consolidation. However, companies are also focusing on global expansion, which in turn is spurring demand for outsourcing services for better compliance and faster drug approvals.
India Healthcare Regulatory Affairs Outsourcing Market: Driven by favorable Government Policies
The government has been implementing certain schemes which are expected to boost market growth. For example, the Universal Health Insurance Scheme is expected to cover people from all parts of society. Talking about the Indian health tech industry, the market is expected to cross a valuation of US$ 8 Bn by 2025 and is expected to grow at a CAGR of nearly 40% during the forecast period.
|
Attributes |
Details |
|
India Market Expected Size (2033) |
US$ 382.9 Mn |
|
India Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 304.6 Mn |
|
CAGR % 2017 to 2022 |
15% |
Even the overseas players have started investing in the Indian market through the FDI route. The medical and surgical appliances sector reported a growth of a massive 202% in FDI infusion during the year 2021-22. Apart from that, the surging disposable income would allow the end users to make the best use of this service. This is expected to surge the healthcare regulatory affairs outsourcing market growth.
Japan’s healthcare regulatory affairs outsourcing market is driven by massive technological innovations
Japan’s pharmaceutical market is witnessing rapid growth. To address the needs of the aging population, the government is focusing on relaxing the regulatory policies and accelerating the development of new drugs into the market. This is expected to increase the demand for various regulatory outsourcing services that are required from the Service Type development to the commercialization stage of the Service Type.
|
Attributes |
Details |
|
Japan Market Expected Size (2033) |
US$ 399 Mn |
|
Japan Market Absolute Dollar Growth (US$ Mn/Bn) |
US$ 280.1 Mn |
|
CAGR % 2017 to 2022 |
12.1% |
To cut the cost, the companies are focusing on outsourcing regulatory activities to the industries. This is expected to propel the growth of the healthcare regulatory affairs outsourcing market in Japan. Advancements in personalized medicine are the major factor driving the growth of the Japanese healthcare regulatory affairs outsourcing market.
Segmentation Analysis
| Segment | Services |
| Attributes | Regulatory Writing and Publishing |
| CAGR % 2017 to 2022 | 10.4% |
| CAGR % 2023 to End of Forecast(2033) | 11% |
| Segment | End User |
| Attributes | Mid-size Pharmaceutical Companies |
| CAGR % 2017 to 2022 | 13.2% |
| CAGR % 2023 to End of Forecast(2033) | 11.6% |
Which is the Most Preferred Healthcare Regulatory Affairs Outsourcing Service?
Based on the services, the regulatory writing and publishing segment is expected to hold the largest market share during the forecast period. This service is offered to start from the nascent stage of product development to marketing. Moreover, the segment is expected to witness growth owing to the greater adoption of outsourcing by large biopharmaceutical and medical device companies.
Moreover, sales in the clinical trial applications segment are projected to remain high over the forecast period. Growing emphasis on improving efficiency and reducing research and development costs is boosting sales in this segment. Clinical trial outsourcing allows companies to leverage therapeutic areas and operational expertise, enabling them to expand their geographical reach and access well-established processes and tools while saving costs.
Besides this, the ongoing development of specialized therapeutic drugs in areas such as oncology is expected to fuel sales in the forthcoming years. Outsourcing allows small and medium-sized companies to conduct clinical trials in areas where the company itself may not have adequate expertise or resources to develop the product independently.
Which End User Segment has the Largest Market Share?
Mid-size pharmaceutical companies are expected to hold the largest healthcare regulatory affairs outsourcing market share during the forecast period. This can be attributed to the growth in biosimilar, personalized medicines, and orphan drugs, which are expected to create more demand for these services.
The biotechnology segment is expected to emerge as one of the most lucrative areas of application in the market, with demand expected to grow at a considerable pace over the assessment period.
The increasing number of documentation during drug and medical device manufacturing is spurring demand for regulatory affairs outsourcing services. Small and medium-sized biotechnology companies struggle with extensive documentation, which is compelling them to invest in outsourcing services.
In addition to this, due to strong regulations, demand for skilled professionals for handling registration, evaluation, and compliance of data is required. Owing to this factor, demand in the biotechnology segment is anticipated to gain momentum over the assessment period.
Start-up Ecosystem
The start-ups operating in the healthcare regulatory affairs outsourcing market are taking the best possible advantage of the lack of skilled professionals in the healthcare sector. Furthermore, the start-ups are also targeting healthcare firms that are based outside large cities.
The new players are focusing more on low-risk outsourcing and strategic outsourcing. The low-risk outsourcing is all about dealing with routine aspects of the business, which also happens to be the heart and soul of the business in a sense. Apart from that, it also allows start-ups to focus more on the regulatory part of the business, which is quite often outsourced. As far as strategic outsourcing is concerned, the companies only focus on the commercial aspects and outsource every other operation to these start-ups.
Competitive Landscape
The key players operating in the healthcare regulatory affairs outsourcing market are focusing on the right approach to improve access the Real World Data from Electronic Medical Records and medical insurance claims, and the technologies like wearables and sensors. For example, Parexel has a dedicated team to assess and understand clinical data, and digital services, that makes use of appropriate statistical methodologies. This would certainly allow the company to engage the right expertise based on the type of data.
Some of the recent developments in the healthcare regulatory affairs outsourcing market are:
- In September 2022, Parexel opened clinical trial supplies and logistics depot in Suzhou.
- In November 2022, IQVIA (formerly Quintiles) and Clait Health Services partnered to advance research by launching the first site in Israel.
The top companies are:
|
Company |
Description |
|
Parexel |
Parexel is the world’s largest Clinical Research Organization (CROs), providing a full range of clinical development services to help life-saving treatments reach patients faster. Our team of more than 19,000 global professionals works with biopharmaceutical firms, upcoming innovators, and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. The depth of industry knowledge we have and strong track record gained over the past 4 decades are advancing clinical research in healthcare’s most complex areas. |
|
IQVIA |
IQVIA is a leading provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. The company is dedicated to creating intelligent connections that deliver unique innovations and actionable insights. IQVIA Connected Intelligence™ connects unparalleled data, advanced analytics, and deep healthcare and scientific expertise so that you can discover previously unseen insights, driven by smarter decision-making. |
|
Clinilabs |
Clinilabs is a global CRO which is into providing a full range of CNS drug development services to pharmaceutical and biotechnology companies, from first-in-human to Phase 3 trials. Clinilabs collaborates with investigator sites to conduct clinical trials that lead to new drug approvals. The company is comprised of industry leaders and experts in the field of clinical research. The team brings the best combination of scientific and operational experience to every project it runs. |
Key Companies Profiled
- PAREXEL International Corporation
- Quintiles IMS Holdings Inc.
- Clinilabs, Inc.
- Accell Clinical Research, LLC
- Freyr Solutions
Healthcare Regulatory Affairs Outsourcing Market Segmentation
By Services:
- Regulatory Writing and Publishing,
- Regulatory Submissions,
- Clinical Trial Applications,
- Product Registrations,
- Regulatory Consulting
- Legal Representation
By End User:
- Mid-size Pharmaceutical Companies,
- Large Pharmaceutical Companies,
- Biotechnology Companies,
- Medical Devices Manufacturer,
- Food and Beverage Companies
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
Frequently Asked Questions
The global healthcare regulatory affairs outsourcing market holds a valuation of US$ 2 Bn as of 2023.
The healthcare regulatory affairs outsourcing market is expected to grow at 11.3% CAGR from 2023 to 2033.
The global healthcare regulatory affairs outsourcing market is forecasted to surpass US$ 5.8 Bn by 2033.
Asia Pacific is the largest healthcare regulatory affairs outsourcing market.
The main drivers are: cost effective solution, and surging investment in R&D.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2017-2022 and Forecast, 2023-2033
4.1. Historical Market Size Value (US$ Mn) Analysis, 2017-2022
4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Services
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Mn) Analysis By Services, 2017-2022
5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Services, 2023-2033
5.3.1. Regulatory Writing and Publishing
5.3.2. Regulatory Submissions
5.3.3. Clinical Trial Applications
5.3.4. Product Registrations
5.3.5. Regulatory Consulting and Legal Representation
5.4. Y-o-Y Growth Trend Analysis By Services, 2017-2022
5.5. Absolute $ Opportunity Analysis By Services, 2023-2033
6. Global Market Analysis 2017-2022 and Forecast 2023-2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Mn) Analysis By End User, 2017-2022
6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By End User, 2023-2033
6.3.1. Mid-Size Pharmaceutical Companies
6.3.2. Large Pharmaceutical Companies
6.3.3. Biotechnology Companies
6.3.4. Medical Devices Manufacturer
6.3.5. Food & Beverage Companies
6.4. Y-o-Y Growth Trend Analysis By End User, 2017-2022
6.5. Absolute $ Opportunity Analysis By End User, 2023-2033
7. Global Market Analysis 2017-2022 and Forecast 2023-2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2017-2022
7.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. MEA
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
8.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
8.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
8.2.1. By Country
8.2.1.1. U.S.
8.2.1.2. Canada
8.2.2. By Services
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Services
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2017-2022 and Forecast 2023-2033, By Country
9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Services
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Services
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2017-2022 and Forecast 2023-2033, By Country
10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
10.2.1. By Country
10.2.1.1. U.K.
10.2.1.2. France
10.2.1.3. Germany
10.2.1.4. Italy
10.2.1.5. Spain
10.2.1.6. Rest of Europe
10.2.2. By Services
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Services
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2033, By Country
11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. India
11.2.1.3. Japan
11.2.1.4. ASEAN
11.2.1.5. Australia & New Zealand
11.2.1.6. Rest of APAC
11.2.2. By Services
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Services
11.3.3. By End User
11.4. Key Takeaways
12. MEA Market Analysis 2017-2022 and Forecast 2023-2033, By Country
12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2022
12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Rest of MEA
12.2.2. By Services
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Services
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. U.S.
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Services
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Services
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Services
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Services
13.4.2.2. By End User
13.5. U.K.
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Services
13.5.2.2. By End User
13.6. France
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Services
13.6.2.2. By End User
13.7. Germany
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Services
13.7.2.2. By End User
13.8. Italy
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Services
13.8.2.2. By End User
13.9. Spain
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Services
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Services
13.10.2.2. By End User
13.11. India
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Services
13.11.2.2. By End User
13.12. Japan
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Services
13.12.2.2. By End User
13.13. ASEAN
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Services
13.13.2.2. By End User
13.14. Australia & New Zealand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Services
13.14.2.2. By End User
13.15. GCC Countries
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Services
13.15.2.2. By End User
13.16. South Africa
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Services
13.16.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Services
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. PAREXEL International Corporation
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Quintiles IMS Holdings Inc.
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Clinilabs, Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Accell Clinical Research, LLC
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Freyr Solutions
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. The Weinberg Group Inc.
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Covance, Inc., (LabCorp)
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Pharmaceutical Product Development LLC
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. ICON plc
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. Sciformix Corporation
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn) Forecast by Region, 2017-2033
Table 2: Global Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 3: Global Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 4: North America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 5: North America Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 6: North America Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 7: Latin America Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 8: Latin America Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 9: Latin America Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 10: Europe Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 11: Europe Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 12: Europe Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 13: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 14: Asia Pacific Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 15: Asia Pacific Market Value (US$ Mn) Forecast by End User, 2017-2033
Table 16: MEA Market Value (US$ Mn) Forecast by Country, 2017-2033
Table 17: MEA Market Value (US$ Mn) Forecast by Services, 2017-2033
Table 18: MEA Market Value (US$ Mn) Forecast by End User, 2017-2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) by Services, 2023-2033
Figure 2: Global Market Value (US$ Mn) by End User, 2023-2033
Figure 3: Global Market Value (US$ Mn) by Region, 2023-2033
Figure 4: Global Market Value (US$ Mn) Analysis by Region, 2017-2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033
Figure 7: Global Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 10: Global Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 11: Global Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 13: Global Market Attractiveness by Services, 2023-2033
Figure 14: Global Market Attractiveness by End User, 2023-2033
Figure 15: Global Market Attractiveness by Region, 2023-2033
Figure 16: North America Market Value (US$ Mn) by Services, 2023-2033
Figure 17: North America Market Value (US$ Mn) by End User, 2023-2033
Figure 18: North America Market Value (US$ Mn) by Country, 2023-2033
Figure 19: North America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 22: North America Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 25: North America Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 26: North America Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 28: North America Market Attractiveness by Services, 2023-2033
Figure 29: North America Market Attractiveness by End User, 2023-2033
Figure 30: North America Market Attractiveness by Country, 2023-2033
Figure 31: Latin America Market Value (US$ Mn) by Services, 2023-2033
Figure 32: Latin America Market Value (US$ Mn) by End User, 2023-2033
Figure 33: Latin America Market Value (US$ Mn) by Country, 2023-2033
Figure 34: Latin America Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 37: Latin America Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 40: Latin America Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 43: Latin America Market Attractiveness by Services, 2023-2033
Figure 44: Latin America Market Attractiveness by End User, 2023-2033
Figure 45: Latin America Market Attractiveness by Country, 2023-2033
Figure 46: Europe Market Value (US$ Mn) by Services, 2023-2033
Figure 47: Europe Market Value (US$ Mn) by End User, 2023-2033
Figure 48: Europe Market Value (US$ Mn) by Country, 2023-2033
Figure 49: Europe Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 52: Europe Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 53: Europe Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 54: Europe Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 55: Europe Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 56: Europe Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 57: Europe Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 58: Europe Market Attractiveness by Services, 2023-2033
Figure 59: Europe Market Attractiveness by End User, 2023-2033
Figure 60: Europe Market Attractiveness by Country, 2023-2033
Figure 61: Asia Pacific Market Value (US$ Mn) by Services, 2023-2033
Figure 62: Asia Pacific Market Value (US$ Mn) by End User, 2023-2033
Figure 63: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033
Figure 64: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 67: Asia Pacific Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 70: Asia Pacific Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 73: Asia Pacific Market Attractiveness by Services, 2023-2033
Figure 74: Asia Pacific Market Attractiveness by End User, 2023-2033
Figure 75: Asia Pacific Market Attractiveness by Country, 2023-2033
Figure 76: MEA Market Value (US$ Mn) by Services, 2023-2033
Figure 77: MEA Market Value (US$ Mn) by End User, 2023-2033
Figure 78: MEA Market Value (US$ Mn) by Country, 2023-2033
Figure 79: MEA Market Value (US$ Mn) Analysis by Country, 2017-2033
Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033
Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033
Figure 82: MEA Market Value (US$ Mn) Analysis by Services, 2017-2033
Figure 83: MEA Market Value Share (%) and BPS Analysis by Services, 2023-2033
Figure 84: MEA Market Y-o-Y Growth (%) Projections by Services, 2023-2033
Figure 85: MEA Market Value (US$ Mn) Analysis by End User, 2017-2033
Figure 86: MEA Market Value Share (%) and BPS Analysis by End User, 2023-2033
Figure 87: MEA Market Y-o-Y Growth (%) Projections by End User, 2023-2033
Figure 88: MEA Market Attractiveness by Services, 2023-2033
Figure 89: MEA Market Attractiveness by End User, 2023-2033
Figure 90: MEA Market Attractiveness by Country, 2023-2033
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
